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RCM1was derived from a failed to fertilise egg subjected to partheno-
genic activation. The cell linewas derived bywhole embryo outgrowth on
mitotically inactivated human fibroblast (HDF) feeder cells using HDF
conditioned medium and expanded under feeder free conditions.
RCM1 was shown to be pluripotent by expression of Oct 4 using
immunocytochemistry (Table 1, Fig. 1). By flow cytometric analysis, the
expression of pluripotency makers Oct4, Tra-1-60 and SSEA-4 was 97%,
98% and 99%, respectively, whereas low expression of the differentiation
marker SSEA-1 (6%) was observed (Fig. 2).org/licenses/by-nc-nd/4.0/).
Table 1
Summary of quality control testing and results for RCM-1.
Classification Test Purpose Result
Donor screening HIV 1 + 2
Hepatitis B
Hepatitis C
Donor screening for adventitious agents Negative
Identity Microsatellite PCR (mPCR) DNA Profiling to give cell line its signature, gender/species Performed
Phenotype Immunocytochemisty To assess levels of staining for the pluripotency markers Oct4
and Nanog
Expression of Oct4 and Nanog
Flow cytometry Assess antigen levels & cell surface markers commonly
associated with hESC
Oct3/4: 97%
Tra 1-60: 98%
SSEA-4: 99%
SSEA-1: 6%
Genotype Blood group genotyping
(DNA analysis)
To establish blood group of the line AA
Karyology (G-banding) Confirmation of normal ploidy by G-banding 46XX
HLA tissue typing To establish full HLA Type I and Type II genotypes of the line HLA typed Class I and Class II
Microbiology and virology Mycoplasma Mycoplasma testing by RT-qPCR Negative
Morphology Photography To capture a visual record of the line Normal
Differentiation potential Embryoid body formation To show differentiation to three germ layers Expression of muscle actin, β-tubulin and α-feto protein
Teratoma formation To show differentiation to three germ layers Teratoma formation observed, three germ layers detected
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soderm,was demonstrated using embryoid body formation and teratoma
formation (Fig. 1).
A microsatellite PCR profile has been obtained for the cell line, and
HLA Class I and Class II typing is available (Table 1). Blood group
genotyping gave the blood group AA (Table 1). The cell line was
analysed for genome stability by G-banding and GCH (Fig. 3), as well
as a SNP array screen to determine whether RCM1 was derived from a
parthenogenetic or fertilized embryo. This showed a normal, 46XX
female genotype with no genetic deficiencies that had originated from
a fertilized egg.
The cell line is free from mycoplasma contamination as determined
by RC-qPCR.
Materials and methods
Ethics
Derivation of hESC from surplus to requirement and failed to fertilise/
develop embryos was approved by The Scotland A Research Ethics Com-
mittee and local ethics board at participating fertility clinics and conduct-
ed under licence no R0136 from the UK HFEA with informed donor
consent.
Cell culture
Activation and derivation of RCM1 is described in De Sousa et al.
(2009), Stem Cell Research 2, 188–197. The established cell line was
expanded and banked using CellStart matrix and Stempro hESC Serum
Free Medium (ThermoFisher Scientific (Life Technologies), Paisley,
UK). Passaging was performed mechanically using an EZ passage tool
(ThermoFisher Scientific).
Mycoplasma
Mycoplasma detection was performed using Applied
Biosystems PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit
and MicroSEQ™ Mycoplasma Real-Time PCR Detection Kit(ThermoFisher Scientific (Applied Biosystems)) according to the
manufacturer's instruction.
Flow cytometry
Pluripotency was determined using the Human and Mouse Plu-
ripotent Stem Cell Analysis kit (BD, Oxford, UK). Oct3/4 and SSEA-4
were included as pluripotency markers, and SSEA-1 as a differenti-
ation marker. FITC conjugated Tra-1-60 (BD) was used as an addi-
tional pluripotency marker. Fixed and permeabilised cells were
analysed using the Guava easyCyte flow cytometer (Millipore,
Watford, UK).
Immunocytochemistry
hESC were fixed in 4% paraformaldehyde (ThermoFisher Scientific
(Alfa Aesar)), permeabilised using 100% ethanol (ThermoFisher
Scientific) and stained with AFP (1:500; Sigma Aldrich, Dorset, UK),
β-tubulin III (1:1000; Sigma), muscle-specific actin (1:50; DAKO,
Glostrup, Denmark), Oct4 (1:200; Santa Cruz Biotechnology, Texas,
USA), Nanog (1:20; R&D Systems, Abingdon, UK) and secondary antibod-
ies anti-mouse IgG-FITC (1:200; Sigma), anti mouse IgG — AlexaFluor
488, anti-goat IgG — AlexaFluor 488 and anti-goat IgG— AlexaFluor-594
(1:200 donkey polyclonal AlexaFluor-594) (all 1:200; ThermoFisher Sci-
entific). Alkaline Phosphatase staining was as per manufacturer's recom-
mended protocol (Vector labs, Peterborough, UK). Images were acquired
using a Zeiss S100 Axiovert fluorescence microscope or Nikon eC1 confo-
cal microscope.
In vitro differentiation
hESC cells were pre-treated for 1 h with 10 μMROCK inhibitor in
Stempro hESC SFM (ThermoFisher Scientific) and embryoid bodies
EBs generated in ultra low attachment plates (Corning) for 7 days
before being transferred into EB medium (20% FBS (GE Healthcare
(PAA), Buckinghamshire, UK), 80% KO-DMEM 1 mM L-glutamine,
0.1 mM β-mercaptoethanol, 1% nonessential amino acids (all
ThermoFisher Scientific)), on glass slide tissue culture chambers
Fig. 1. The characterization of RCM1 as a pluripotent hESC line. Undifferentiated colonies of RCM1 on human dermal fibroblast feeder cells are shown (A) in phase contrast, (B) stained
positively for Oct4 and (C) stained positively for alkaline phosphatase activity. RCM1 cells in vitro differentiated via embryoid bodies and stained for markers of the three germ layers:
(D) muscle-specific actin (mesoderm), (E) α-fetoprotein (endoderm), and (F) β-tubulin III (ectoderm). A histological assessment was made of teratoma tissue formed as a result of
transplantation of the hESC line, RCM1, into the testis of adult SCID mice. (G) Low-power image showing heterogeneity of tissue structure in tumor. Identifiable structures include
bone (bn), cartilage (ct), connective tissue (cn), and small cysts (cy); higher power images show (H) neuroectoderm (ne) and neural ganglion (ng) and (I) bone (bn). (J) Cartilage;
(K) wall of primitive intestine, including muscular layer (mu), submucosal tissue (sm), and goblet cells (gc) within epithelium releasing mucus secretion (mc); (L) primitive kidney
consisting of renal corpuscle (rc) and associated tubules (tb). (G–J, L) Weigert's and (K) hematoxylin and eosin. Scale bars, 100 μm (A–J) and 50 μm (K and L).
From De Sousa et al. (2009).
Fig. 2. Flowcytometry analysis of undifferentiated RCM1. RCM-1was subjected to flowcytometry analysis formarkers of pluripotency. The specific antibody stained histograms are shown
in the top row against the corresponding control histograms. Percentage staining is indicated in Table 1.
478 P.A. De Sousa et al. / Stem Cell Research 16 (2016) 476–480
Fig. 3.Karyotype analysis of RCM-1. RCM-1was analysed byGiemsa staining of 20metaphase spreads and showed a normal 46XX female karyotype (top panel). No genomic copy number
imbalance was evaluated using a BlueGnome CytoChips array designed to improve detection of copy number variation associated with constitutional genetic disorders (bottom panel).
Presented are SNP polymorphism copy number representation which did not exceed normal ranges (flanking green and red lines) depicted next to chromosome ideograms.
From De Sousa et al. (2009).
479P.A. De Sousa et al. / Stem Cell Research 16 (2016) 476–480(Nunc, ThermoFisher Scientific) coated with 0.5% gelatin (Sigma)
at 0.1 ml/cm2 for 14 days.In vivo differentiation
The developmental potential of RCM-1 to form teratomas consisting
of tissues representative of all three germ layers was evaluated
480 P.A. De Sousa et al. / Stem Cell Research 16 (2016) 476–480following transplantation under kidney capsule in adult SCID mice and
teratoma formation assessed as described in De Sousa et al. (2009),
Stem Cell Research 2, 188–197.
Genomic analysis
All outsourced assays were carried out under a Quality and Technical
Agreement. DNA was extracted using the QIAamp DNAMini kit (Qiagen,
Manchester, UK) according to the manufacturer's recommendations.
Microsatellite PCR, or Short TandemRepeat analysis, was used to de-
termine cell line identity and was carried out by Public Health England.
A profile was obtained for the following core alleles: vWA, D16S539,
Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and TPOX.
Human Leukocyte Antigen (HLA) tissue typing was carried out by
the Scottish National Blood Transfusion Service.
Blood group genotyping was carried out by theMolecular Diagnostics
laboratory at NHSBT.
Karyotype analysis was carried out by The Doctors Laboratory
(London, UK) or the Western General Cytogenetics Laboratory
(Edinburgh, UK) Live cells at 60–70% confluency were shipped overnight
in warm containers, fixed and analysed by standard G-banding analysis.
For research grade lines, 20 spreads were analysed.
Comparative genome hybridization (CGH)was carried out in collab-
oration with ARK Genomics (Roslin Institute, UK), using BlueGnome
CytoChipTM arrayCGH v2. Genome-wide SNP analysis genomic DNAwas carried out with GeneChip Human Mapping 250 K Sty I and 250 K
Nsp arrays (Affymetrix), both as described in De Sousa et al. (2009),
Stem Cell Research 2, 188–197.
Verification and authentication
The identity and phenotype of RCM1 was confirmed by quality
control testing using the aforementioned methods the results of which
are summarised in Table 1, Figs. 1 & 2. Further information on this line
can be obtained from its original publication in De Sousa et al., 2009.
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